New urinary biomarkers show promise for bladder cancer detection and recurrence prediction. Learn more about this non-invasive diagnostic approach.

The U.S. Food and Drug Administration (FDA) has warned a biotech company about claims that its bladder cancer drug could treat and prevent multiple types of cancer.

Shares of ImmunityBio IBRX fell more than 21% on Tuesday after the FDA issued a warning letter over “false” or “misleading” ...

BTIG maintained its 'Buy' rating and $13 price target, implying about 75% upside, and said the warning relates to promotion ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.

ImmunityBio (IBRX) stock falls as the FDA issues a warning letter regarding a TV commercial and a podcast related to the ...

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

MHN has signed support of 2 policies: a Bladder Cancer Research Program within DoD & recognition of post-baccalaureate nursing degrees as professional degrees. Expanding the workforce of nurses & ...

After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his story to life in his first commercial for the company. Sanders starred in ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...